Boston Mayor Michelle Wu is facing mounting pressure from city employee unions over the rapidly escalating costs of covering GLP-1 receptor agonist medications like Ozempic and Wegovy. The dispute highlights a financial challenge confronting employers nationwide as demand for these weight loss and diabetes drugs continues to surge, with City Hall reportedly struggling to manage healthcare expenditures that have ballooned due to the expensive medications.
According to the Boston Herald, the conflict centers on whether the city can maintain coverage for these drugs, which typically cost between $900 and $1,300 per month per patient. Municipal unions are pushing back against any potential restrictions or elimination of coverage, arguing that employees have come to rely on these medications for both medical weight management and diabetes control. The standoff underscores the broader tension between providing comprehensive healthcare benefits and managing taxpayer-funded budgets.
GLP-1 medications have become one of the fastest-growing categories of prescription drugs in the United States, with millions of Americans seeking access to treatments that have demonstrated significant weight loss results. However, their popularity has created unprecedented cost pressures for insurers, employers, and government health programs. Many organizations are now grappling with how to balance employee health needs against budgets that weren’t designed to accommodate such expensive therapies at scale.
The Boston situation reflects a national trend, as employers from major corporations to local governments reassess their pharmacy benefit strategies. Some have implemented prior authorization requirements, step therapy protocols, or coverage limitations specifically for weight loss indications while maintaining access for diabetes treatment. The debate in Boston may serve as a bellwether for how other municipalities and public employers approach this challenge in the coming months, particularly as newer, even more effective GLP-1 formulations enter the market at similarly high price points.
